Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Food Effect Study of D-0502 Tablet in Healthy Volunteers

5. august 2019 opdateret af: InventisBio Co., Ltd

A Phase I, Randomized, Open Label, Two-Sequence, Two-Period Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of D-0502 Tablet in Postmenopausal Female Healthy Subjects

This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting), two-period, two-sequence crossover study of postmenopausal female healthy subjects.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

14

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Florida
      • Daytona Beach, Florida, Forenede Stater, 32117
        • Covance Daytona Beach Clinical Research Unit

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  1. Subjects must be medically documented as healthy and acceptable at physical examination.
  2. Subjects must have a BMI between 18.0 and 32.0 kg/m2 and a body weight of 45 kg or higher.
  3. Subjects must have all laboratory parameters within the normal range or considered not clinically significant by the principal investigator.
  4. Subjects must have a normal urinalysis, eGFR, ECG or results considered not clinically significant by the principal investigator.
  5. Subjects must be female with postmenopausal status defined as meeting at least one of the following criteria:

    1. Have undergone a bilateral oophorectomy any time in life;
    2. Age ≥60 years, or
    3. Age <60 years but have cessation of regular menses ≥12 months with follicle stimulating hormone (FSH) value >40 milli-international units per milliliter (mIU/mL) and an estradiol value <40 picograms per milliliter (pg/mL) (140 picomoles per liter [pmol/L]).
  6. Subjects are able to understand the study procedures and risks involved and must provide signed informed consent to participate in the study.

Exclusion Criteria:

  1. Subjects with any history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological or psychiatric disorders, as determined by the investigator.
  2. Subjects who have any history or suspicion of kidney stones.
  3. Subjects who are positive for human immunodeficiency virus (HIV), Hepatitis B, and/or Hepatitis C.
  4. Subjects who have used prescription drugs, over-the-counter drugs, or natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 14 days before Day 1 of study medication dosing.
  5. Subjects had undergone major surgery within 3 months prior to Day 1.
  6. Subjects who is participating in a clinical research study involving the administration of an investigational or marketed drug or device, or who received any investigational test article within 5 half-lives or 30 days prior to Day 1 study medication dosing.
  7. Subjects with positive urine drug screen test at screening.
  8. Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Sequence AB
D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.
D-0502 oral tablets
Eksperimentel: Sequence BA
D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.
D-0502 oral tablets

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pharmacokinetic: area under the plasma concentration versus time curve (AUC)
Tidsramme: Day 1 through 4, Day 7 through 11
AUC: area under the plasma concentration versus time curve for D-0502; Unit: nM*hr
Day 1 through 4, Day 7 through 11
Pharmacokinetic: maximum plasma drug concentration (Cmax)
Tidsramme: Day 1 through 4, Day 7 through 11
Cmax: maximum plasma drug concentration of D-0502; Unit: nM
Day 1 through 4, Day 7 through 11
Pharmacokinetic: Time to reach the Cmax (Tmax)
Tidsramme: Day 1 through 4, Day 7 through 11
Tmax: Time to reach the Cmax of D-0502; Unit: hr
Day 1 through 4, Day 7 through 11
Pharmacokinetic: Apparent terminal half-life (t1/2)
Tidsramme: Day 1 through 4, Day 7 through 11
t1/2: apparent terminal half-life of D-0502; Unit: hr
Day 1 through 4, Day 7 through 11

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Treatment-Emergent Adverse Events
Tidsramme: 2 weeks
Number of treatment-related adverse events as assessed by CTCAE v4.0
2 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. oktober 2018

Primær færdiggørelse (Faktiske)

21. november 2018

Studieafslutning (Faktiske)

17. april 2019

Datoer for studieregistrering

Først indsendt

16. december 2018

Først indsendt, der opfyldte QC-kriterier

17. januar 2019

Først opslået (Faktiske)

18. januar 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

7. august 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. august 2019

Sidst verificeret

1. august 2019

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IBIO-302

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner